CN115590931B - 一种解酒护肝的组合物 - Google Patents
一种解酒护肝的组合物 Download PDFInfo
- Publication number
- CN115590931B CN115590931B CN202211135905.0A CN202211135905A CN115590931B CN 115590931 B CN115590931 B CN 115590931B CN 202211135905 A CN202211135905 A CN 202211135905A CN 115590931 B CN115590931 B CN 115590931B
- Authority
- CN
- China
- Prior art keywords
- extract
- composition
- nad
- water
- alcohol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 title claims abstract description 55
- 239000000203 mixture Substances 0.000 title claims abstract description 51
- 230000000694 effects Effects 0.000 title claims abstract description 23
- 210000004185 liver Anatomy 0.000 title claims abstract description 12
- 240000007126 Citrus medica var. sarcodactylis Species 0.000 claims abstract description 22
- 238000000034 method Methods 0.000 claims abstract description 10
- 239000000463 material Substances 0.000 claims abstract description 9
- 239000000284 extract Substances 0.000 claims description 37
- 238000000605 extraction Methods 0.000 claims description 24
- 241000026010 Dendrobium candidum Species 0.000 claims description 22
- 241000157835 Gardenia Species 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 9
- 235000013399 edible fruits Nutrition 0.000 claims description 9
- 239000002994 raw material Substances 0.000 claims description 9
- 235000013305 food Nutrition 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 6
- 206010019133 Hangover Diseases 0.000 claims description 4
- 238000009835 boiling Methods 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 229940127557 pharmaceutical product Drugs 0.000 claims description 2
- 244000179970 Monarda didyma Species 0.000 claims 1
- 235000010672 Monarda didyma Nutrition 0.000 claims 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 abstract description 30
- 230000003213 activating effect Effects 0.000 abstract description 16
- 229950006238 nadide Drugs 0.000 abstract description 13
- 230000037356 lipid metabolism Effects 0.000 abstract description 9
- 239000000843 powder Substances 0.000 abstract description 4
- 230000008569 process Effects 0.000 abstract description 4
- 230000001737 promoting effect Effects 0.000 abstract description 3
- 241001076416 Dendrobium tosaense Species 0.000 abstract 1
- 240000001972 Gardenia jasminoides Species 0.000 abstract 1
- 230000004060 metabolic process Effects 0.000 description 14
- 102000019197 Superoxide Dismutase Human genes 0.000 description 12
- 108010012715 Superoxide dismutase Proteins 0.000 description 12
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 11
- 210000003494 hepatocyte Anatomy 0.000 description 11
- 229940118019 malondialdehyde Drugs 0.000 description 11
- 210000005229 liver cell Anatomy 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 150000003626 triacylglycerols Chemical class 0.000 description 8
- 238000007254 oxidation reaction Methods 0.000 description 7
- 206010067125 Liver injury Diseases 0.000 description 6
- 231100000753 hepatic injury Toxicity 0.000 description 6
- 230000003859 lipid peroxidation Effects 0.000 description 6
- 239000003642 reactive oxygen metabolite Substances 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 230000036542 oxidative stress Effects 0.000 description 5
- 230000002075 anti-alcohol Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000001476 alcoholic effect Effects 0.000 description 3
- HPYIIXJJVYSMCV-MGDXKYBTSA-N astressin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]1C(N[C@@H](C)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@@H](CCCCNC(=O)CC1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(N)=O)=O)C(C)C)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CNC=N1 HPYIIXJJVYSMCV-MGDXKYBTSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000005515 coenzyme Substances 0.000 description 3
- 230000035622 drinking Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000005502 peroxidation Methods 0.000 description 3
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010016262 Fatty liver alcoholic Diseases 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000004136 fatty acid synthesis Effects 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 108020002663 Aldehyde Dehydrogenase Chemical group 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000029650 alcohol withdrawal Diseases 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000004149 ethanol metabolism Effects 0.000 description 1
- 230000004129 fatty acid metabolism Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 230000004202 respiratory function Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8984—Dendrobium
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medical Informatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Addiction (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种可激活烟酰胺腺嘌呤二核苷酸(NAD+)表达的组合物,含有以下物料:铁皮石斛叶粉、佛手粉及栀子粉。本方案所提供可促进NAD+表达的组合物,可加快人体代谢酒精与脂质的过程,从而达到解酒护肝的效果。
Description
技术领域
本专利属于功能性组合物技术领域,具体地,涉及一种可激活NAD+表达的组合物及其解酒护肝的应用。
背景技术
近日有报告显示,中国人均酒精消费量增加,戒酒率下降。这是因为我国酒文化源远流长,更有“人在江湖走,哪能不喝酒”的经典语录。然而急性大量饮酒和长期饮酒会给人体带来毒副作用,如酒精性肝损伤等。随着我国科技进步与经济发展,人们越来越关注自身的健康,且试图采用各种方法来解除或减轻饮酒后对人体产生的毒副作用。因此,开发一款可以有效提高酒精代谢速率和降低酒精性肝损伤的产品,对于提高国民健康水平和生活质量有重大意义。
在酒精代谢过程,ADH和ALDH依赖于辅酶烟酰胺腺嘌呤二核苷酸(NAD+)发挥催化酒精代谢功能,NAD+在此过程中会被消耗掉,转变为NADH(烟酰胺腺嘌呤二核苷酸的还原态)。因此,NAD+的数量会随着酒精代谢的持续进行而逐渐减少,从而限制酒精代谢速度。
而肝脏脂质代谢水平主要取决于脂肪酸的β-氧化途径,同样以NAD+作为辅酶。正常情况下,肝细胞线粒体中NAD+水平能够满足脂肪酸的β-氧化,但当人体摄入酒精后,肝细胞中NAD+被快速消耗,使得脂肪酸合成甘油三酯(TG)增多,形成脂肪沉积在肝细胞中,最终形成酒精性脂肪肝。总而言之,NAD+是影响肝脏酒精代谢速率、脂质代谢水平的关键限制因素。
基于以上,有必要寻求一种能够促进NAD+表达的组合物以达到提高酒精代谢速率和降低酒精性肝损伤,满足消费者的需求。
发明内容
本发明的目的是开发一种可激活NAD+表达的组合物及其解酒护肝药的制备,以通过促进机体细胞的NAD+表达量,达到提高机体的酒精代谢效率的效果。
根据本发明的一个方面,提供一种可激活NAD+表达的组合物,所述组合物包括铁皮石斛、佛手、栀子或上述物料的提取物中的至少一种。铁皮石斛、佛手、栀子都能够促进机体细胞尤其是肝细胞表达NAD+,由此,将上述本发明提供的上述组合物作用于机体,能够显著提高机体中的NAD+含量。另外,本发明提供的上述组合物还能够提升机体的超氧化物歧化酶(SOD)活力。依据现有技术可知,酒精代谢过程中机体中积累的活性氧(ROS)通过诱发脂质过氧化反应生成脂质过氧化产物丙二醛(MDA),会引起蛋白质、核酸等生命大分子的交联聚合。而SOD能够清除机体中的活性氧(ROS),避免由于ROS积累而产生的细胞毒性。所述组合物能够显著激活NAD+和SOD表达,使MDA、TG、谷草转氨酶(AST)和谷丙转氨酶(ALT)水平显著下降。
优选地,在所述可激活NAD+表达的组合物中,包括铁皮石斛、佛手、栀子或上述物料的提取物组合。
优选地,在所述可激活NAD+表达的组合物中,按照质量比计算,所述铁皮石斛或其提取物:所述佛手或其提取物:所述栀子或其提取物=1~2: 0.5~1:0.5~1。
优选地,在所述可激活NAD+表达的组合物中,按照质量比计算,所述铁皮石斛或其提取物:所述佛手或其提取物:所述栀子或其提取物=1~2: 0.6~1:0.6~1。
优选地,在所述可激活NAD+表达的组合物中,按照质量比计算,所述铁皮石斛或其提取物:所述佛手或其提取物:所述栀子或其提取物= 1.2~1.8:0.6~0.7:0.6~0.7。
优选地,在所述可激活NAD+表达的组合物中,按照质量比计算,所述铁皮石斛或其提取物:所述佛手或其提取物:所述栀子或其提取物=2:1:1。
在上述组合物中,同时包括有铁皮石斛、佛手、栀子或上述三种物料的提取物,对于上述三种物料而言,与单独作用相比,三者共同作用产生相互协同效果,能够进一步地促进机体表达NAD+以及提高机体的SOD酶活性。
可选地,在所述可激活NAD+表达的组合物中,所述提取物来源包括但不限于:根、茎、叶、花、果实、种子等。
优选地,在所述可激活NAD+表达的组合物中,所述铁皮石斛的提取物为利用铁皮石斛叶提取得到。
优选地,在所述可激活NAD+表达的组合物中,所述佛手的提取物为利用佛手果实提取得到。
优选地,在所述可激活NAD+表达的组合物中,所述栀子的提取物为利用栀子果实提取得到。
优选地,在所述可激活NAD+表达的组合物中,所述铁皮石斛的提取物按照如下方法制备:采用铁皮石斛叶作为原料,以水作为提取溶剂,进行二次提取,第一次提取加入8~12倍水煮沸1~3h,第二次提取加入6~10倍水煮沸0.5~2h,由此制得所述铁皮石斛的提取物。
优选地,在所述可激活NAD+表达的组合物中,所述佛手的提取物按照如下方法制备:采用佛手果实作为原料,以水作为提取溶剂,进行二次提取,第一次提取加入10~14倍水煮沸1~3h,第二次提取加入8~12倍水煮沸0.5~2h,由此制得所述佛手的提取物。
优选地,在所述可激活NAD+表达的组合物中,所述栀子的提取物按照如下方法制备:采用栀子果实作为原料,以水作为提取溶剂,进行二次提取,第一次提取加入8~12倍水煮沸1~3h,第二次提取加入6~10倍水煮沸0.5~2h,由此制得所述栀子的提取物。
可选地,在所述可激活NAD+表达的组合物中,所述提取物其存在的形式可以为固体、液体、气体。
根据本发明的另一个方面,提供上述可激活NAD+表达的组合物在制备食品或者药品上的应用。
可选地,在上述应用中,其食品或药剂形式可以为口服液、饮品、果冻、糖果、胶囊、软胶囊、片剂、固体饮料,压片糖果。
优选地,在上述应用中,所加入的助剂选自:木糖醇、果胶、柠檬酸、三氯蔗糖、甜菊糖苷、蜂蜜、食品用香精中的至少一种。
根据本发明的另一个方面,提供一种解酒护肝食品或药品,该解酒护肝食品或药品包括上述用于提高NAD+表达量的组合物。人在饮酒后,酒精在人体内发生代谢,酒精(乙醇)及其代谢产物乙醛,会抑制肝脏细胞线粒体的呼吸功能,大量消耗NAD+,阻碍肝脏脂肪酸正常代谢(β-氧化),使得脂肪酸合成TG增多,形成脂肪沉积在肝细胞中,最终形成酒精性脂肪肝。此外,乙醇和乙醛代谢过程中会产生较多的ROS,诱发脂质过氧化反应,生成脂质过氧化产物MDA,会引起蛋白质、核酸等生命大分子的交联聚合,具有细胞毒性。应用上述组合物作为解酒护肝药的有效作用成分,由此制得的解酒药能够通过促进服用其的饮酒者的机体细胞尤其是肝细胞表达NAD+以及时补充因代谢酒精而消耗的NAD+,同时,也能够通过提高机体中的SOD酶活性,达到清除MDA,促进肝脏脂肪酸代谢,改善肝脏抗氧化能力和增强脂质代谢水平的效果。
优选地,在上述解酒护肝药中,其主要加工工艺中调pH的范围为3~4。
综上所述,相比于现有技术,本发明所提供的方案具有如下有益效果:将铁皮石斛叶、佛手和栀子这三种物料按一定比例进行复配后,发现该组合物既能激活NAD+表达,又能提升SOD的活力。在各原料组分的协同作用下,能够显著激活NAD+和SOD表达,使MDA、TG、AST和ALT水平显著下降,从而强化解酒护肝功效,显著下调酒精诱导的肝脏氧化应激水平、增强脂质代谢水平,显著减轻乙醇诱导的肝细胞损伤程度,实现快速解酒和预防肝损伤的功效。
具体实施方式
为了使本技术领域的人员更好地理解本发明中的技术方案,下面将结合本发明实施例和实施例中的附图对本发明的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都应当属于本发明保护的范围。
实施例1
1.可激活NAD+表达组合物的制备
本实施例采用铁皮石斛叶、佛手果实及栀子果实作为原料,上述原料分别经过如下工序:粉碎、热水提取、浓缩、干燥、过筛制成粉末状。
随后将上述三种原料按配比称取,混匀制成可激活NAD+表达组合物,各试样所采用混合物组成如表1所示。
表1 实施例组合物质量比
测试例1
1.细胞培养
肝细胞HepG2保存在DMEM培养基中,DMEM培养基中添加10%胎牛血清、100 U/mL青霉素和0.1 mg/mL链霉素,置于37℃、5% CO2饱和湿度的培养箱中传代培养。2天换液1次,3~4天用0.1%胰蛋白酶消化,1:3传代培养。
2.组合物对乙醇处理肝细胞HepG2中酒精代谢酶、氧化应激水平和脂质代谢的影响
取对数生长期的HepG2细胞,以0.1%胰蛋白酶溶液消化细胞,离心,制成单细胞悬液,计数。调整细胞浓度为5×105个/mL,接种于6孔培养板中,备用。实验设置正常对照组、模型组和样品组:
(1)对照组:正常培养基培养
(2)模型组:在对照组基础上添加2%浓度乙醇培养
(3)样品组:在模型组基础上加入浓度为4 mg/mL的组合物培养,组合物质量比如表1所设。
上述各实验组均置于37℃、5% CO2饱和湿度的培养箱中,培养48小时。48小时后,去除培养液,用PBS缓冲液小心清洗两遍,加入RIPA 裂解液,充分裂解后,于3000r/min 离心3~5min,取上清液,用NAD+、SOD、MDA、TG、AST、ALT试剂盒测定。
其中,由于MDA含量可以反映机体氧化应激水平,也能反映组织过氧化损伤程度;而SOD水平是反映机体抗氧化潜在能力的重要参数。此外,AST和ALT主要存在肝细胞中,正常情况下由于肝细胞膜屏障作用,AST、ALT只有极少量能透过细胞膜进入血液中。而当肝细胞受到损伤后,细胞膜通透性增加,此时AST、ALT进入血液中显著增加,且肝细胞损伤程度与AST、ALT透过量成正比。因此,临床上常用AST、ALT含量作为判断肝损伤程度的重要标志物。
3.实验结果
如表2所示,与正常组相比,乙醇处理HepG2细胞后,NAD+含量显著下降,表明乙醇在肝细胞中的代谢消耗了大量的NAD+;SOD含量显著降低、MDA含量显著上升,表明乙醇处理导致肝细胞氧化应激水平显著上升;TG含量显著上升,表明乙醇处理导致肝细胞脂质代谢紊乱。如前所述,肝细胞内脂肪酸的β-氧化过程是脂质代谢主要途径,该过程需以NAD+为辅酶。当乙醇代谢消耗了大量的NAD+后,使得脂肪酸β-氧化过程受阻,诱导脂质代谢紊乱,形成脂肪沉积,进而发生脂质过氧化反应,生产脂质过氧化产物MDA,最终导致肝细胞受损(AST、ALT水平显著上升是肝细胞受损的标志物)。
当组合物干预后,上述各指标均有不同程度的改善,具体而言,通过加入铁皮石斛叶、佛手、栀子或上述物料的提取物中的至少一种,都能够显著激活NAD+和SOD表达,使MDA、TG、AST和ALT水平显著下降。其中,当可激活NAD+表达的组合物,按照质量比计算,铁皮石斛叶:佛手:栀子=2:1:1,NAD+含量最高,各项指标改善效果最优,且与正常组基本无显著差异。该结果表明,此比例下可激活NAD+表达的组合物对于乙醇诱导的肝脏氧化、脂质代谢及肝损伤有最好的改善效果。
表2 组合物对乙醇处理肝细胞酒精代谢酶、氧化应激水平和脂质代谢的影响
注:a,与正常组相比p<0.05;b,与模型组相比p<0.05。
以上实施例仅用以说明本发明的技术方案而非对本发明保护范围的限制,尽管参照上述实施例对本发明进行了详细的说明,所属领域的普通技术人员应当理解,可以对本发明的技术方案进行修改或者等同替换,但这些修改或替换均在本发明的保护范围之内。
Claims (3)
1.一种解酒护肝的组合物,其特征在于:所述组合物由铁皮石斛、佛手、栀子或上述物料的提取物组成;其中,在所述组合物中,按照质量比计算,所述铁皮石斛或其提取物:所述佛手或其提取物:所述栀子或其提取物=2:1:1;
其中,所述铁皮石斛的提取物按照如下方法制备:采用铁皮石斛叶作为原料,以水作为提取溶剂,进行二次提取,第一次提取加入8~12倍水煮沸1~3h,第二次提取加入6~10倍水煮沸0.5~2h,由此制得所述铁皮石斛的提取物;
所述佛手的提取物按照如下方法制备:采用佛手果实作为原料,以水作为提取溶剂,进行二次提取,第一次提取加入10~14倍水煮沸1~3h,第二次提取加入8~12倍水煮沸0.5~2h,由此制得所述佛手的提取物;
所述栀子的提取物按照如下方法制备:采用栀子果实作为原料,以水作为提取溶剂,进行二次提取,第一次提取加入8~12倍水煮沸1~3h,第二次提取加入6~10倍水煮沸0.5~2h,由此制得所述栀子的提取物。
2.如权利要求1所述组合物在制备食品或者药品上的应用。
3.一种解酒护肝食品或药品,其特征在于:所述解酒护肝食品或药品包括如权利要求1所述组合物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211135905.0A CN115590931B (zh) | 2022-09-19 | 2022-09-19 | 一种解酒护肝的组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211135905.0A CN115590931B (zh) | 2022-09-19 | 2022-09-19 | 一种解酒护肝的组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115590931A CN115590931A (zh) | 2023-01-13 |
CN115590931B true CN115590931B (zh) | 2024-06-14 |
Family
ID=84842375
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211135905.0A Active CN115590931B (zh) | 2022-09-19 | 2022-09-19 | 一种解酒护肝的组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115590931B (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1586546A (zh) * | 2004-07-15 | 2005-03-02 | 贵州省兴义市吉仁堂药业公司 | 一种治疗肝胆疾病的药物及其制备方法 |
CN101455354A (zh) * | 2007-12-14 | 2009-06-17 | 中国科学院微生物研究所 | 天然菌草保肝解酒剂 |
CN111544543A (zh) * | 2020-05-14 | 2020-08-18 | 贵州康达利生物科技有限公司 | 一种具有清肺、解烟毒及解酒益肝功能的组合物 |
-
2022
- 2022-09-19 CN CN202211135905.0A patent/CN115590931B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1586546A (zh) * | 2004-07-15 | 2005-03-02 | 贵州省兴义市吉仁堂药业公司 | 一种治疗肝胆疾病的药物及其制备方法 |
CN101455354A (zh) * | 2007-12-14 | 2009-06-17 | 中国科学院微生物研究所 | 天然菌草保肝解酒剂 |
CN111544543A (zh) * | 2020-05-14 | 2020-08-18 | 贵州康达利生物科技有限公司 | 一种具有清肺、解烟毒及解酒益肝功能的组合物 |
Non-Patent Citations (6)
Title |
---|
不同提取方法对佛手多糖性质和乙醇脱氢酶活性的影响;陈孝云;王洪新;吕文平;马朝阳;江琦;;安徽农业科学;第46卷(第23期);第131-135页 * |
杨静 ; 唐灿 ; 晏飞利 ; 尹莉君 ; 丁超 ; 韩晓菲 ; 杨仕卓 ; .栀子醒酒饮品的醒酒及护肝作用.现代食品科技.2019,第35卷(第05期),第46-51、273页. * |
栀子醒酒饮品的醒酒及护肝作用;杨静;唐灿;晏飞利;尹莉君;丁超;韩晓菲;杨仕卓;;现代食品科技;第35卷(第05期);第46-51、273页 * |
袁慧琦 ; 梁楚燕 ; 梁健 ; 侯少贞 ; 黄松 ; 赖小平 ; .铁皮石斛对小鼠急性酒精性肝损伤的保护作用.暨南大学学报(自然科学与医学版).2016,第37卷(第05期),第384-388页. * |
铁皮石斛对小鼠急性酒精性肝损伤的保护作用;袁慧琦;梁楚燕;梁健;侯少贞;黄松;赖小平;;暨南大学学报(自然科学与医学版);第37卷(第05期);第384-388页 * |
陈孝云 ; 王洪新 ; 吕文平 ; 马朝阳 ; 江琦 ; .不同提取方法对佛手多糖性质和乙醇脱氢酶活性的影响.安徽农业科学.2018,第46卷(第23期),第131-135页. * |
Also Published As
Publication number | Publication date |
---|---|
CN115590931A (zh) | 2023-01-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108887673B (zh) | 富含超氧化物歧化酶sod的野木瓜酵素的制备方法 | |
CN113143812B (zh) | 一种卡瓦胡椒发酵物的制备方法和产品及其在化妆品中的应用 | |
CN114632055B (zh) | 一种美白舒缓的植物发酵物及其制备方法和应用 | |
CN111135123B (zh) | 一种卷柏发酵提取液的制备方法和应用 | |
TW202302134A (zh) | 諾麗果發酵物於製備改善體態及肌膚狀況之組合物之用途 | |
CN112608949B (zh) | 一种三七花提取物的制备方法及其应用 | |
CN115590931B (zh) | 一种解酒护肝的组合物 | |
CN102178937B (zh) | 一种护肝益脾的药物组合物及其制备方法 | |
KR101784688B1 (ko) | 간 기능 개선 및 숙취해소를 촉진하는 약용버섯 고체발효 조성물 제조방법 | |
CN107854508B (zh) | 一种缓解酒精肝损伤的组合物及其制备方法 | |
CN114514973B (zh) | 一种具有醒酒护肝功效的葛根复合发酵饮料的制备方法 | |
CN114788806A (zh) | 一种具有抗氧化美白一体功效的中药组合物发酵原浆及其制备方法和应用 | |
CN113648311A (zh) | 7-(2,2-二甲基-3-丁烯酰胺基)-八氢苯喹啉乙酸酯在制备降脂药物中的应用 | |
CN114010548A (zh) | 层孔菌深层发酵浓缩液与菌体提取物组合物及其制备方法、应用 | |
CN113616712A (zh) | 一种金花藏茶制品 | |
CN113812481A (zh) | 一种金花藏茶制品的制备方法 | |
CN107648283B (zh) | 保护受损肝细胞的产品及其应用 | |
WO2020052073A1 (zh) | 一种促进肝脏脂质代谢、抗炎降酶的提取物及其制备方法 | |
KR102488608B1 (ko) | 인삼발효추출액 및 버섯균사체배양물을 유효성분으로 함유하는 숙취해소용 조성물 | |
CN111773323A (zh) | 石斛水提取物在治疗2型糖尿病的应用 | |
KR101228554B1 (ko) | 진피발효생성방법 및 이에 의한 진피발효생성물 | |
CN116570633B (zh) | 植物乳杆菌在缓解肝损伤中的应用 | |
CN109674839A (zh) | 一种酪氨酸酶抑制剂及其制备方法和用途 | |
KR102585372B1 (ko) | 인삼효소발효액, 영지버섯 균사체 배양물 및 구름송편버섯 균사체 배양물을 유효성분으로 함유하는 숙취해소용 조성물 | |
KR20200016610A (ko) | 지방간 개선제 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |